IDEAS home Printed from https://ideas.repec.org/
MyIDEAS: Log in (now much improved!) to follow this JEL code

Research classified by Journal of Economic Literature (JEL) codes


Top JEL
/ L: Industrial Organization
/ / L6: Industry Studies: Manufacturing
/ / / L65: Chemicals; Rubber; Drugs; Biotechnology
This topic is covered by the following reading lists:
  1. Industrial Sociology (FCT-UNL)

Most recent items first, undated at the end.
  • 2016 Mergers And Acquisitıons In Pharmaceutical Industry As A Growth Strategy: An Investigation Upon Practice
    by Yasin ÇİLHOROZ & Cuma SONĞUR & Mehmet GÖZLÜ & Murat KONCA

  • 2016 When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization
    by Leemore Dafny & Christopher Ody & Matthew Schmitt

  • 2016 A Ricardian-Demand Explanation for Changing Pharmaceutical R&D Productivity
    by Mark Pauly & Kyle Myers

  • 2016 Entry and Patenting in the Pharmaceutical Industry
    by Maria Letizia GIORGETTI & Maria Luisa MANCUSI

  • 2016 Access to Medicines and European Market Integration
    by Fabio Pammolli & Armando Rungi

  • 2016 Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals
    by Bergman , Mats A. & Granlund, David & Rudholm, Niklas

  • 2016 Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals
    by Bergman, Mats & Granlund, David & Rudholm, Niklas

  • 2016 Patents and the global diffusion of new drugs
    by Iain Cockburn & Jean O. Lanjouw & Mark Schankerman

  • 2016 Strukturwandel in der Europäischen Union am Beispiel ausgewählter Leitmärkte mit besonderem Bezug auf die Innovationstätigkeit der Mitgliedsländer
    by Jens K. Perret

  • 2016 Using simulation experiments to test historical explanations: the development of the German dye industry 1857-1913
    by Thomas Brenner & Johann Peter Murmann

  • 2016 The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995–2012
    by Frank R. Lichtenberg

  • 2016 Price offers of pharmaceutical procurement in China: evidence from Guangdong province
    by Ying Yao & Makoto Tanaka

  • 2016 Entry time effects and follow-on drug competition
    by Luiz Flavio Andrade & Catherine Sermet & Sylvain Pichetti

  • 2016 Mergers And Acquisitıons In Pharmaceutical Industry As A Growth Strategy: An Investigation Upon Practice
    by Yasin ÇİLHOROZ & Cuma SONĞUR & Mehmet GÖZLÜ & Murat KONCA

  • 2016 'You’ll (n)ever walk alone'. Innovative Wissensarbeit zwischen individualistischem Leistungsregime und kommunitaerer Teamkultur ('You’ll (n)ever walk alone'. Innovative knowledge work: Individual performance systems as opposed to communitarian team culture)
    by Doerhoefer, Steffen & Funder, Maria

  • 2016 “Effective regulatory stringency” and firms’ profitability: the effects of effluent limits and government monitoring
    by Dietrich Earnhart & Dylan G. Rassier

  • 2016 Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose
    by Mats A. Bergman & David Granlund & Niklas Rudholm

  • 2016 On compensation schemes for data sharing within the European REACH legislation
    by Sylvain Béal & Marc Deschamps

  • 2016 The Growth Prospects for the World Tire Market in the Short and Medium-Term
    by Florela Stoian

  • 2016 Impacto De La Mujer Directiva En La Salida A Bolsa De Empresas De Alta Tecnología: El Efecto Mediador De Las Patentes Y El Desarrollo De Productos / Impact Of Female Managers On High-Technology Firms Going Public: The Mediating Effect Of Patents And Product Development
    by Quintana García, Cristina

  • 2016 Proposal Of Base Business Model For Biotechnology Companies In Mexico, Propuesta De Modelo De Negocio Base Para Las Empresas De Biotecnologia En Mexico
    by Sergio Castro Aranda & Virginia Guadalupe Lopez Torres & Graciela Guerra Rivas

  • 2016 Innovation in the pharmaceutical industry: New estimates of R&D costs
    by DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W.

  • 2016 Análisis de la variación de la eficiencia en la producción de biocombustibles en América Latina
    by José Morelos Gómez

  • 2016 Patents as a Spur to Subsequent Innovation? Evidence from Pharmaceuticals
    by Duncan S. Gilchrist

  • 2016 Does Merger Simulation Work? Evidence from the Swedish Analgesics Market
    by Jonas Björnerstedt & Frank Verboven

  • 2016 The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India
    by Mark Duggan & Craig Garthwaite & Aparajita Goyal

  • 2016 Patents and the Global Diffusion of New Drugs
    by Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman

  • 2015 Vertical Specialization, Global Value Chains and the changing Geography of Trade: the Portuguese Rubber and Plastics Industry Case
    by João Lopes & Ana Santos

  • 2015 Les innovations de produits dans la chimie du végétal comme substituts aux plastiques
    by Manon JUBIEN

  • 2015 The role of diversification profiles and dyadic characteristics in the formation of technological alliances: Differences between exploitation and exploration in a low-tech industry
    by Krammer, Sorin M.S.

  • 2015 Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform
    by Kurt R. Brekke & Chiara Canta & Odd Rune StraumeAuthor-Email: o.r.straume@eeg.uminho.p

  • 2015 Corporate Venture Capital as a Real Option in the Markets for Technology
    by Marco Ceccagnoli & Matthew J. Higgins & Hyunsung D. Kang

  • 2015 The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011
    by Frank R. Lichtenberg

  • 2015 An Overview of the Stratified Economics of Stratified Medicine
    by Mark R. Trusheim & Ernst R. Berndt

  • 2015 Assets with "Warts": How Reliable is the Market for Technology?
    by Vincenzo Palermo & Matthew J. Higgins & Marco Ceccagnoli

  • 2015 An Empirical Analysis of Primary and Secondary Pharmaceutical Patents in Chile
    by María José Abud Sittler & Bronwyn Hall & Christian Helmers

  • 2015 Competition and R&D Financing Decisions: Theory and Evidence from the Biopharmaceutical Industry
    by Richard T. Thakor & Andrew W. Lo

  • 2015 Same Place, Same Knowledge – Same People? The Geography of Non-Patent Citations in Dutch Polymer Patents
    by Dominik Heinisch & Önder Nomaler & Guido Buenstorf & Koen Frenken & Harry Lintsen

  • 2015 Vertical Specialization, Global Value Chains and the changing Geography of Trade: the Portuguese Rubber and Plastics Industry Case
    by João Carlos Lopes & Ana Santos

  • 2015 Initial Public Offering and Financing of Biotechnology Start-ups: Evidence from Japan
    by HONJO, Yuji & NAGAOKA, Sadao

  • 2015 Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform
    by Brekke, Kurt R. & Canta, Chiara & Straume, Odd Rune

  • 2015 Resilience, creativity and innovation. The case of Chemical innovations after the 1966 Flood in Florence
    by Luciana Lazzeretti & Francesco Capone

  • 2015 Pharmaceutical Sector In Serbia In The Period 1990-2013
    by Stefan Dragutinovic, Jovan Zubovic, Marija Reljic

  • 2015 Same Place, Same Knowledge – Same People? The Geography of Non-Patent Citations in Dutch Polymer Patents
    by Dominik Heinisch & Önder Nomaler & Guido Buenstorf & Koen Frenken & Harry Lintsen

  • 2015 A Quantitative Analysis of the Retail Market for Illicit Drugs
    by Galenianos, Manolis & Gavazza, Alessandro

  • 2015 Price Regulation and Parallel Imports of Pharmaceuticals
    by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume

  • 2015 Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry
    by Simon P. Anderson & Federico Ciliberto & Jura Liaukonyte & Régis Renault

  • 2015 Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010
    by Frank Lichtenberg

  • 2015 The Effects of Publicity on Demand: The Case of Anti-cholesterol Drugs
    by Andrew Ching & Robert Clark & Ignatius Horstmann & Hyunwoo Lim

  • 2015 Unravelling the Worldwide Pollution Haven Effect
    by Jean-Marie Grether & Nicole Andréa Mathys & Jaime de Melo

  • 2015 FDI, the Brain Drain and Trade: Channels and Evidence
    by Artjoms IVLEVS & Jaime DE MELO

  • 2015 Openness, Inequality and Poverty: Endowments Matter
    by Julien Gourdon & Nicolas Maystre & Jaime de Melo

  • 2015 The Political Economy of Migration and EU Enlargement: Lessons from Switzerland
    by Jaime de Melo & Florence Miguet & Tobias Müller

  • 2015 Attitudes Towards Immigration: A Trade Theoretic Approach
    by Sanoussi Bilal & Jean-Marie Grether & Jaime de Melo

  • 2015 The Political Economy of International Migration in a Ricardo–Viner Model
    by Jean-Marie Grether & Jaime de Melo & Tobias Müller

  • 2015 Why OECD Countries Should Reform Rules of Origin
    by Olivier Cadot & Jaime de Melo

  • 2015 The Protectionist Bias of Duty Drawbacks: Evidence from Mercosur
    by Olivier Cadot & Jaime de Melo & Marcelo Olarreaga

  • 2015 The New Regionalism: A Country Perspective
    by JAIME DE MELO & ARVIND PANAGARIYA & DANI RODRIK

  • 2015 Has Distance Died? Evidence from a Panel Gravity Model
    by Jean-François Brun & Céline Carrère & Patrick Guillaumont & Jaime de Melo

  • 2015 Are Different Rules of Origin Equally Costly? Estimates from NAFTA
    by Céline Carrère & Jaime de Melo

  • 2015 Do Exporters Gain from VERs?
    by Jaime de Melo & L. Alan Winters

  • 2015 The Effects of Trade Reforms on Scale and Technical Efficiency
    by James Tybout & Jaime de Melo & Vittorio Corbo

  • 2015 The Influence of Increased Foreign Competition on Industrial Concentration and Profitability
    by Jaime de MELO & Shujiro URATA

  • 2015 Pricing Policy Under Double Market Power: Madagascar and the International Vanilla Market
    by Jaime de Melo & Marcelo Olarreaga & Wendy Takacs

  • 2015 Fiscal Spending and Economic Growth: Some Stylized Facts
    by Céline Carrère & Jaime de Melo

  • 2015 Adjustment, Investment and the Real Exchange Rate in Developing Countries
    by Riccardo Faini & Jaime de Melo

  • 2015 Growth-Oriented Adjustment Programs: A Statistical Analysis
    by RICCARDO FAINI & JAIME DE MELO & ABDELHAK SENHADJI & JULIE STANTON

  • 2015 Adjustment with a Fixed Exchange Rate: Cameroon, Côte d'Ivoire, and Senegal
    by Shantayanan Devarajan & Jaime de Melo

  • 2015 The Effects of Financial Liberalization on Savings and Investment in Uruguay
    by Jaime de Melo & James Tybout

  • 2015 What Went Wrong with the Recent Reforms in the Southern Cone
    by Vittorio Corbo & Jaime de Melo & James Tybout

  • 2015 Effective Technology Transfer in Biotechnology:Best Practice Case Studies in Europe
    by

  • 2015 Developing Countries in the World Economy
    by Jaime de Melo

  • 2015 Harnessing stem cell potential for regenerative medicine and cell-based therapy
    by Jitendra Kumar Chaudhary

  • 2015 La construction des catégories diagnostiques de maladie mentale
    by Brun, Cédric & Demazeux, Steeves & Vittorio, Pierangelo Di & Gonon, François & Gorry, Philippe & Konsman, Jan Peter & Lung, Fanny & Lung, Yannick & Minard, Michel & Montalban, Matthieu & Rumeau, Nicole & Smith, Andy

  • 2015 The dynamics of total factor productivity and its components: Russian plastic production
    by Ipatova, Irina

  • 2015 Unpacking performance benefits of innovation ambidexterity: Evidence from the pharmaceutical industry
    by Suzuki, Osamu

  • 2015 Internationalisation of R&D: New insights into multinational enterprises’ R&D strategies in emerging markets
    by Haakonsson, Stine Jessen & Ujjual, Vandana

  • 2015 A novel application of grey principal component analysis to determine stockholder’s approach towards financial ratios
    by Amin Babaei Falah & Morteza Sardari

  • 2015 How the Distribution System and the Granting of Drug Discounts, is an Influencing Factor for a Pharmaceutical Units’ Financial Performance
    by Margaritti Doina & Tomos Sirma

  • 2015 Market Structure, Government Shareholding and Cost Efficiency in Taiwan's Biotech Industry
    by Chen-Ming Chen & Tzu-Chun Sheng & Yung-Lieh Yang

  • 2015 In vitro alteration of some taxoni in danger of extinction from protected areas from Bihor country (drosera rotundifolia huds.)
    by Agud Eliza Maria

  • 2015 Price regulation and parallel imports of pharmaceuticals
    by Brekke, Kurt R. & Holmås, Tor Helge & Straume, Odd Rune

  • 2015 Location choice of academic entrepreneurs: Evidence from the US biotechnology industry
    by Kolympiris, Christos & Kalaitzandonakes, Nicholas & Miller, Douglas

  • 2015 Policy induced price volatility transmission: Linking the U.S. crude oil, corn and plastics markets
    by Jiang, Jingze & Marsh, Thomas L. & Tozer, Peter R.

  • 2015 Integration von Industrie- und Innovationspolitik: Beispiele aus den USA und Israel und Ansätze der neuen EU-Industriepolitik
    by Sven Wydra & Timo Leimbach

  • 2015 Substitutability Between Drugs, Innovation, and Fiscal Policy in the Pharmaceutical Industry
    by Felipa de Mello-Sampayo & Sofia de Sousa-Vale & Francisco Camoes

  • 2015 La calidad desde el diseño: principios y oportunidades para la industria farmacéutica
    by Oscar Fabián García Aponte & Bibiana Margarita Vallejo Díaz & Claudia Elizabeth Mora Huertas

  • 2015 Pricing in the Market for Anticancer Drugs
    by David H. Howard & Peter B. Bach & Ernst R. Berndt & Rena M. Conti

  • 2015 Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
    by Eric Budish & Benjamin N. Roin & Heidi Williams

  • 2014 Internationale Expansion in der pharmazeutischen Industrie Österreichs
    by Christian Zeller & Andreas Hametner & Koen Smet & Markus Seiwald

  • 2014 Biotechnological firms in Uruguay 2010-2012
    by Carlos Bianchi

  • 2014 Productivity Spillovers in the Russian Federation: The Case of Chemical Market
    by Kuzyaeva, Anastasia & Didenko, Alexander

  • 2014 Porto Marghera and the Industrial Ecology Challenge: Why it did not become an Eco-Industrial Park
    by Mannino, Ilda & Ninka, Eniel & Turvani, Margherita

  • 2014 Price Regulation and Parallel Imports of Pharmaceuticals
    by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume

  • 2014 Starving (or Fattening) the Golden Goose?: Generic Entry and the Incentives for Early-Stage Pharmaceutical Innovation
    by Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins

  • 2014 Patents and the Global Diffusion of New Drugs
    by Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman

  • 2014 Do "Reverse Payment" Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay?
    by Keith M. Drake & Martha A. Starr & Thomas McGuire

  • 2014 Defacto and Deeded Intellectual Property: Knowledge-Driven Co-Evolution of Firm Collaboration Boundaries and IPR Strategy
    by Lynne G. Zucker & Michael R. Darby

  • 2014 Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007
    by Rena M. Conti & Ernst R. Berndt

  • 2014 Gravity and Extended Gravity: Using Moment Inequalities to Estimate a Model of Export Entry
    by Eduardo Morales & Gloria Sheu & Andrés Zahler

  • 2014 Direct to Consumer Advertising of Pharmaceutical Drugs: Information and Persuasion
    by Talia Bar & Dean R. Lillard

  • 2014 Firm-level Productivity Spillovers in China's Chemical Industry: A Spatial Hausman-Taylor Approach
    by Badi H. Baltagi & Peter H. Egger & Michaela Kesina

  • 2014 Firm-Level Productivity Spillovers in China's Chemical Industry: A Spatial Hausman-Taylor Approach
    by Badi H. Baltagi & Peter H. Egger

  • 2014 Price Regulation and Parallel Imports of Pharmaceuticals
    by Brekke, Kurt R. & Holmås, Tor Helge & Straume, Odd Rune

  • 2014 The Technological Resilience of U.S. Cities
    by Balland, Pierre-Alexandre & Rigby, David & Boschma, Ron

  • 2014 Reforming the Swedish pharmaceuticals market – consequences for costs per defined daily dose
    by Bergman, Mats & Granlund, David & Rudholm, Niklas

  • 2014 Drug approval decision times, international reference pricing and strategic launches of new drugs
    by Nicolas Houy & Izabela Jelovac

  • 2014 German Jewish émigrés and US invention
    by Petra Moser & Alessandra Voena & Fabian Waldinger

  • 2014 Patents and the global diffusion of new drugs
    by Iain Cockburn & Jean O. Lanjouw & Mark Schankerman

  • 2014 The Technological Resilience of U.S. Cities
    by Pierre-Alexandre Balland & David Rigby & Ron Boschma

  • 2014 Balanced collective contributions, the equal allocation of non-separable costs and application to data sharing games
    by Sylvain Béal & Marc Deschamps & Philippe Solal

  • 2014 On compensation schemes for data sharing within the european REACH legislation
    by Sylvain Béal & Marc Deschamps

  • 2014 Patents and the Global Diffusion of New Drugs
    by Cockburn, Iain M & Lanjouw, Jean O & Schankerman, Mark

  • 2014 Carestía e inflación: qué esperar de la política agrícola y los gravámenes a la tierra y el carbono
    by Carlos Gustavo Cano

  • 2014 Firm-level Productivity Spillovers in China's Chemical Industry: A Spatial Hausman-Taylor Approach
    by Badi H. Baltagi & Peter Egger & Michaela Kesina

  • 2014 Sources of Productivity Spillovers: Panel Data Evidence from China
    by Badi H. Baltagi & Peter Egger & Michaela Kesina

  • 2014 The Impact of R&D Cooperations on Drug Variety Offered on the Market. Evidence from the Pharmaceutical Industry
    by Tannista Banerjee & Ralph Siebert

  • 2014 Patents and the Global Diffusion of New Drugs
    by Iain Cockburn & Jean O. Lanjouw & Mark Schankerman

  • 2014 How the pharmaceutical business model has changed
    by Philippe Abecassis & Nathalie Coutinet

  • 2014 Les transformations du modèle de l’industrie pharmaceutique
    by Philippe Abecassis & Nathalie Coutinet

  • 2014 Entry Threats and Pricing in the Generic Drug Industry
    by Steven Tenn & Brett W. Wendling

  • 2014 Montedison. Il dinosauro nel MEC
    by Paolo Sylos Labini

  • 2014 A New Vision Regarding the Competitive Advantages in the Romanian Pharmaceutical Market
    by Margaritti Doina

  • 2014 Methodology of Investment Programs' Studying and Its Optimization in Bounded Financial Resources (the Example of Chemical Industry)
    by Braginskij, O. & Tatevosjan, G. & Sedova, S.

  • 2014 Export Drivers And Barriers: Evidence From Ghanaian Pharmaceutical Manufacturing Firms
    by Samuel Yaw Akomea & Olav Jull Sørensen & Kweku Amponsah-Efah

  • 2014 Pharmaceutical economics
    by William S. Comanor & Stuart O. Schweitzer

  • 2014 R&D portfolios and pharmaceutical licensing
    by Nishimura, Junichi & Okada, Yosuke

  • 2014 Scientific knowledge dynamics and relatedness in biotech cities
    by Boschma, Ron & Heimeriks, Gaston & Balland, Pierre-Alexandre

  • 2014 Konjunkturtest im Fokus: Herstellung von Gummi- und Kunststoffwaren
    by Evgenia Kudymowa & Klaus Wohlrabe

  • 2014 Stimmt die Chemie? Die Export- und Forschungsstärke der Chemischen und Pharmazeutischen Industrie im Ost-West-Vergleich
    by Julia Heller & Jan Kluge & Christian Ochsner

  • 2014 Patrimoines productifs collectifs versus exploration/exploitation. Le cas de la bioraffinerie
    by Martino Nieddu & Estelle Garnier & Christophe Bliard

  • 2014 Consumer Inertia and Firm Pricing in the Medicare Part D Prescription Drug Insurance Exchange
    by Keith M. Marzilli Ericson

  • 2014 German Jewish ?migr?s and US Invention
    by Petra Moser & Alessandra Voena & Fabian Waldinger

  • 2013 Inter-firm R&D networks in pharmaceutical biotechnology: What determines firm's centrality-based partnering capability
    by Krogmann, Yin & Riedel, Nadine & Schwalbe, Ulrich

  • 2013 Compulsory licensing: India’s maiden experience
    by Savita Gautam & Meghna Dasgupta

  • 2013 La chimie verte: une nouvelle industrie de substitution GREEN CHEMISTRY: A NEW INDUSTRY OF SUBSTITUTE
    by Clément WILS

  • 2013 Business and Intellectual Capital Development in Financial Riptide - Case Studies of Finnish Biotechnology and Pharmaceutical Companies Dispersing into Global Value Chains
    by Kulvik, Martti & Tähtinen, Marja & Ylä-Anttila, Pekka

  • 2013 The Effects of Drug Enforcement on Violence in Colombia 1999-2010: A Spatial Econometric Approach
    by Botero Degiovanni, Hernan

  • 2013 Environmental Bio Economic Impact in Nicaragua
    by Blanco Orozco, Napoleón Vicente & Zuniga Gonzalez, Carlos Alberto

  • 2013 Proximity, network formation and inventive performance: in search of the proximity paradox
    by Cassi, Lorenzo & Plunket, Anne

  • 2013 Explorative Versus Exploitative Alliances—Evidence From The Glass Industry In China
    by Leung, Vincent K.K. & Lau, Chi Keung Marco & Zhang, Zhe

  • 2013 Pharmaceutical Followers
    by Peter Arcidiacono & Paul B. Ellickson & Peter Landry & David B. Ridley

  • 2013 The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity
    by Murray L. Aitken & Ernst R. Berndt & Barry Bosworth & Iain M. Cockburn & Richard Frank & Michael Kleinrock & Bradley T. Shapiro

  • 2013 Price Indexes for Clinical Trial Research: A Feasibility Study
    by Ernst R. Berndt & Iain M. Cockburn

  • 2013 Behind the Scenes: Sources of Complementarity in R&D
    by Marco Ceccagnoli & Matthew J. Higgins & Vincenzo Palermo

  • 2013 Drug launch timing and international reference pricing
    by Nicolas Houy & Izabela Jelovac

  • 2013 Relatedness and Technological Change in Cities: The rise and fall of technological knowledge in U.S. metropolitan areas from 1981 to 2010
    by Ron Boschma & Pierre-Alexandre Balland & Dieter Franz Kogler

  • 2013 Scientific Knowledge Dynamics and Relatedness in Bio-Tech Cities
    by Ron Boschma & Gaston Heimeriks & Pierre-Alexandre Balland

  • 2013 The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence
    by Frank Lichtenberg & Gisela Hostenkamp

  • 2013 Pharmaceutical regulation and innovative performance: a decision-theoretic model
    by Tannista Banerjee & Stephen Martin

  • 2013 The Impact of R&D Cooperation on Drug Variety Offered on the Market: Evidence from the Pharmaceutical Industry
    by Tannista Banerjee & Ralph Siebert

  • 2013 Determinants of Generic vs. Brand Drug Choice: Evidence from Population-wide Danish Data
    by Niels Skipper & Rune Vejlin

  • 2013 The Relative Role of Imports and Exports in Explaining Productivity of Indian Bio-Pharmaceutical Firms: Evidence from Non Parametric Data Envelopment Analysis
    by Arpita Ghose & Chandrima Chakraborti

  • 2013 Technical efficiency of Russian plastic and rubber production firms
    by Ipatova, Irina & Peresetsky, Аnatoly

  • 2013 Nuevas perspectivas sobre el precio de los medicamentos: El caso español/New Perspectives on Drug Pricing: The Spanish Case
    by CABIEDES MIRAGAYA, LAURA

  • 2013 Competition in the pharmaceutical industry: How do quality differences shape advertising strategies?
    by de Frutos, Maria-Angeles & Ornaghi, Carmine & Siotis, Georges

  • 2013 Multi-market contact and competition: evidence from the Depression-era portland cement industry
    by Chicu, Mark & Ziebarth, Nicolas L.

  • 2013 Pharmaceutical followers
    by Arcidiacono, Peter & Ellickson, Paul B. & Landry, Peter & Ridley, David B.

  • 2013 Information content of advertising: Empirical evidence from the OTC analgesic industry
    by Anderson, Simon P. & Ciliberto, Federico & Liaukonyte, Jura

  • 2013 Informing the uninformed: How drug advertising affects check-up visits
    by Hosken, Daniel & Wendling, Brett

  • 2013 Direct-to-consumer advertising and consumer welfare
    by Jayawardhana, Jayani

  • 2013 Margins and market shares: Pharmacy incentives for generic substitution
    by Brekke, Kurt Richard & Holmås, Tor Helge & Straume, Odd Rune

  • 2013 Mandatory disclosure of plant emissions into the environment and worker chemical exposure inside plants
    by Finger, Stephen R. & Gamper-Rabindran, Shanti

  • 2013 Identification of External Critical Success Factors in Microbial Biotechnology Firms
    by Alireza AZIMI

  • 2013 Análisis multivariado de la productividad y rendimientos financieros de empresas industriales en Cartagena, Colombia
    by José Morelos Gómez & Fabián Gazabón Arrieta & Roberto Enrique Gómez Fernández

  • 2013 Can Financial Engineering Cure Cancer?
    by David E. Fagnan & Jose Maria Fernandez & Andrew W. Lo & Roger M. Stein

  • 2012 Sources of Heterogeneity in the Efficiency of Indian Pharmaceutical Firms
    by MAZUMDAR, MAINAK & RAJEEV, MEENAKSHI & RAY, SUBHASH C.

  • 2012 Launching prices for new pharmaceuticals in heavily regulated and subsidized markets
    by Jaume Puig & Beatriz González López-Valcárcel

  • 2012 Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010
    by Berndt, Ernst & Dubois, Pierre

  • 2012 The Role of the South African Government in Developing the Biotechnology Industry – from Biotechnology Regional Innovation Centres to the Technology Innovation Agency
    by Ramazan Uctu & Hassan Essop

  • 2012 Engineering Knowledge
    by Nathan Rosenberg & W. Edward Steinmuller

  • 2012 How Do The Institutions Involved In Scientific Collaboration Deal With Different Kinds Of Distance? An Analysis Of The Co-Autorships Of Scientific Publications
    by Rosamaria D’Amore & Roberto Iorio & Sandrine Labory & Agnieszka Stawinoga

  • 2012 Who And Where Are The Co-Authors? The Relationship Between Institutional And Geographical Distance In Scientific Publications
    by Rosamaria D’Amore & Roberto Iorio & Agnieszka Stawinoga

  • 2012 Le rôle de l’Etat dans la promotion du secteur pharmaceutique en Algérie: que nous enseigne l’approche par les systèmes sectoriels d’innovation THE ROLE OF THE STATE IN THE PROMOTION OF THE PHARMACEUTICAL SECTOR IN ALGERIA: WHAT DOES THE SECTORAL SYSTEMS OF INNOVATION APPROACH TEACH US?
    by Samia GHARBI

  • 2012 Competitiveness and future challenges of Pohjois-Savo - A report for The Regional Council of Pohjois-Savo (in Finnish with English abstract and summary)
    by Hernesniemi, Hannu & Kulvik, Martti & Ylä-Anttila, Pekka

  • 2012 Research collaboration in co-­inventor networks: combining closure,bridging and proximities
    by Cassi, Lorenzo & Plunket, Anne

  • 2012 Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry
    by Anderson, Simon & Ciliberto, Federico & Liaukonyte, Jura & Renault, Regis

  • 2012 The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey
    by Frank R. Lichtenberg

  • 2012 R&D for Neglected Diseases
    by Nicola Dimitri

  • 2012 Entry Time Effects and Follow-on Drugs Competition
    by Luiz Flavio Andrade

  • 2012 Déterminants de l’écart de prix entre médicaments similaires et le premier entrant d’une classe thérapeutique
    by Christine Sorasith & Sylvain Pichetti & Thomas Cartier & Laure Bergua & Catherine Sermet

  • 2012 Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010
    by Berndt, Ernst & Dubois, Pierre

  • 2012 The effect of pharmacies’ right to negotiate discounts on the market share of parallel imported pharmaceuticals
    by Granlund, David

  • 2012 The effect of pharmacies’ right to negotiate discounts on the market share of parallel imported pharmaceuticals
    by Granlund, David

  • 2012 EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals - What’s to Blame? Derogation or Perception?
    by Granlund, David & Yesim Köksal, Miyase

  • 2012 Regional trajectories of innovation in Green Chemistry: Evidence from the Aquitaine region (In French)
    by Vanessa OLTRA & Maïder SAINT-JEAN

  • 2012 Mapping the scientific knowledge of the Green Chemistry community (In French)
    by Marianna EPICOCO (GREThA, CNRS, UMR 5113) & Vanessa OLTRA (GREThA, CNRS, UMR 5113) & Maïder SAINT JEAN (GREThA, CNRS, UMR 5113)

  • 2012 Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland
    by Aki Kangasharju & Joni Hokkanen & Ismo Linnosmaa & Hannu Valtonen

  • 2012 The path- and place-dependent nature of scientific knowledge production in biotech 1986-2008
    by Gaston Heimeriks & Ron Boschma

  • 2012 Path-breaking innovations for lung cancer: a revolution in clinical practice
    by Mario Coccia

  • 2012 Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010
    by Berndt, Ernst R & Dubois, Pierre

  • 2012 Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry
    by Anderson, Simon P & Ciliberto, Federico & Liaukonyte, Jura & Renault, Régis

  • 2012 Hacia una política integral de medicamentos biotecnológicos en Colombia
    by Juan Gonzalo Zapata & Sergio Bernal & Jairo Castillo & Katherine Garzón

  • 2012 The rising Chinese pharmaceutical industry: local champions vs global players
    by Francesca Spigarelli & Hao Way

  • 2012 Margins and Market Shares: Pharmacy Incentives for Generic Substitution
    by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume

  • 2012 The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data
    by Frank Lichtenberg & Billie Pettersson

  • 2012 Investments in Pharmaceuticals Before and After TRIPS
    by Margaret K. Kyle & Anita M. McGahan

  • 2012 Dynamics of Public Policy-Making in Malaysia: The Formulation of National Biotechnology Policy
    by Ravi MAHALINGAM

  • 2012 Quasi-fixed inputs in the Italian manufacturing: The case of the pharmaceutical industry
    by Carbonari, Lorenzo

  • 2012 The Impact Of Total Quality Management On Competitive Advantage Of Pharmaceutical Manufacturing Companies In Jordan
    by KAMAL A. M. AL-QUDAH

  • 2012 Energy saving opportunities in Jordanian pharmaceutical industries
    by Mohammad Al-Tahat & Areen Al-Ali

  • 2012 Entry and submarket concentration: empirical evidence from the pharmaceutical industry
    by Maria Letizia Giorgetti

  • 2012 Human resource management for learning through knowledge exploitation and knowledge exploration: Pharmaceuticals in Mexico
    by Santiago, Fernando & Alcorta, Ludovico

  • 2012 The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry
    by Toole, Andrew A.

  • 2012 What do drug monopolies cost consumers in developing countries?
    by Hellerstein, Rebecca

  • 2012 Productivity Growth in Some Energy Intensive Manufacturing Industries in India: An Analytical Assessment
    by Sarbapriya Ray

  • 2012 Drug Innovations and Welfare Measures Computed from Market Demand: The Case of Anti-cholesterol Drugs
    by Abe Dunn

  • 2012 The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors
    by Craig L. Garthwaite

  • 2011 The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry
    by Toole, Andrew A.

  • 2011 Inter-firm R&D networks in the global pharmaceutical biotechnology industry during 1985 - 1998: A conceptual and empirical analysis
    by Krogmann, Yin & Schwalbe, Ulrich

  • 2011 Generic drugs in Spain: price competition vs. moral hazard
    by Ivan Moreno-Torres

  • 2011 What if there was a stronger pharmaceutical price competition in Spain? When regulation has a similar effect to collusion
    by Ivan Moreno-Torres

  • 2011 Global Framework for Differential Pricing of Pharmaceuticals
    by Daems, Rutger & Maes, Edith & Ramani, Shyama V.

  • 2011 Mapping the interdisciplinary nature and co-evolutionary patterns in five nano-industrial sectors
    by Wang, Lili & Notten, Ad

  • 2011 Sources of Heterogeneity in the Efficiency of Indian Pharmaceutical Firms
    by Mainak Mazumdar & Meenakshi Rajeev & Subhash Ray

  • 2011 Market Size and Pharmaceutical Innovation
    by Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul

  • 2011 Innovation and Corporate Dynamics: A Theoretical Framework
    by Jakub Growiec & Fabio Pammolli & Massimo Riccaboni

  • 2011 A Few Special Cases: Scientific Creativity and Network Dynamics in the Field of Rare Diseases
    by Massimo Riccaboni & Maria Laura Frigotto

  • 2011 Inefficiencies in technology transfer: theory and empirics
    by Marie-Laure Allain & Emeric Henry & Margaret K. Kyle

  • 2011 Determinants of drug launch delay in pre-TRIPS India: A survival analysis approach
    by Saradindu Bhaduri & Thomas Brenner

  • 2011 Accumulation and Circulation of the Knowledge Needed for Biotech Business Promotion by Engineers of R&D Section in an IT Enterprise: The Case of Hitachi Software Engineering Co., Ltd
    by Ohta, Hirofumi & Motohashi, Kazuyuki

  • 2011 Gravity and extended gravity: estimating a structural model of export entry
    by Morales, Eduardo & Sheu, Gloria & Zahler, Andrés

  • 2011 Innovation and Corporate Dynamics: A Theoretical Framework
    by Massimo, Riccaboni & Jakub, Growiec & Fabio, Pammolli

  • 2011 Trade and Innovation: Pharmaceuticals
    by Nobuo Kiriyama

  • 2011 Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets
    by Patricia M. Danzon & Michael F. Furukawa

  • 2011 A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets
    by Ernst R. Berndt & Thomas G. McGuire & Joseph P. Newhouse

  • 2011 Explaining vertical integration in the generic pharmaceutical industry
    by Kensuke Kubo

  • 2011 Market Size and Pharmaceutical Innovation
    by Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul

  • 2011 EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals - What’s to Blame? Derogation or Perception?
    by Granlund, David & Yesim Köksal, Miyase

  • 2011 Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?
    by Granlund, David & Köksal , Miyase Yesim

  • 2011 Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?
    by Granlund, David & Köksal, Miyase Yesim

  • 2011 Subjective well-being among preadolescents - Evidence from urban China
    by Carlsson, Fredrik & Lampi, Elina & Li, Wanxin & Martinsson, Peter

  • 2011 EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals. What's blame? Derogation or perception?
    by Granlund, David & Yesim Köksal, Miyase

  • 2011 Parallel Imports and Mandatory Substitution Reform: A kick or a muff for price competition in pharmaceuticals
    by Granlund, David & Yesim Köksal, Miyase

  • 2011 The Dynamics of the Inventor Network in German Biotechnology: Geographical Proximity versus Triadic Closure
    by Anne L.J. Ter Wal

  • 2011 On the institutional innovation process : EU regulation through an evolutionary lens
    by Paraskevopoulou, Evita

  • 2011 Investments in Pharmaceuticals Before and After TRIPS
    by Kyle, Margaret K & McGahan, Anita M

  • 2011 Market Size and Pharmaceutical Innovation
    by de Mouzon, Oliver & Dubois, Pierre & Scott Morton, Fiona & Seabright, Paul

  • 2011 Inefficiencies in technology transfer: theory and empirics
    by Allain, Marie-Laure & Henry, Emeric & Kyle, Margaret K

  • 2011 Seguimiento al desarrollo tecnológico a través de patentes el caso de la biotecnología
    by Claudia Nelcy Jiménez Hernández

  • 2011 Markets for Pharmaceutical Products11The authors thank Tom McGuire for editorial advice and improvements and participants at the Handbook conference for helpful suggestions
    by Scott Morton, Fiona & Kyle, Margaret

  • 2011 Multiscalar Clusters And Networks As The Foundations Of Innovation Dynamics In The Biopharmaceutical Industry
    by Marc-Hubert DEPRET & Abdelillah HAMDOUCH

  • 2011 An Application of Economic Capacity Utilization to the Measurement of Total Factor Productivity Growth: Empirical Evidence from Indian Fertilizer Industry
    by Sarbapriya, Ray & Mihir, Kumar Pal

  • 2011 Marx’s social analysis of value and Big Pharma. Rethinking the social determinants of value in cognitive capitalism
    by Gagnon, Marc-André

  • 2011 Growth and Financing Behaviour of Firms of Textile Industry in Pakistan: A Panel Data Analysis
    by Ijaz Hussain

  • 2011 The Production Of Medicines In Romania After 1990. What'S The Reason For Imports?
    by Unita Lucian & Straciuc Oreste & Maghiar Teodor Traian & Uivarosan Diana

  • 2011 Strategic Development Trends in the World Pharmaceutical Industry
    by Dragan Kesic

  • 2011 Spatial collocation and venture capital in the US biotechnology industry
    by Kolympiris, Christos & Kalaitzandonakes, Nicholas & Miller, Douglas

  • 2011 Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment
    by Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune

  • 2011 Too Many Products: Decentralized Decision Making in Multinational Firms
    by Catherine Thomas

  • 2011 Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration
    by Glenn Ellison & Sara Fisher Ellison

  • 2010 The impact of pricing and patent expiration on the demand for pharmaceuticals: An examination of the use of broad-spectrum antimicrobials
    by Kaier, Klaus

  • 2010 Opportunities and Benefits as Determinants of the Direction of Scientific Research
    by Mikko Packalen & Jay Bhattacharya

  • 2010 Determinants of PRO-industry interactions in pharmaceutical R&D: the case of Mexico
    by Santiago-Rodriguez, Fernando & Dutrenit, Gabriela

  • 2010 Child Externalising and Internalising Behaviour in the First Year of School: The Role of Parenting in a Low SES Population
    by Carly Cheevers & Orla Doyle & Kelly McNamara

  • 2010 Decomposing Gender Differences in College Student Earnings Expectations
    by Liam Delaney & Colm Harmon & Cathy Remond

  • 2010 Size Metrics and Dynamics of Firms Expansion in the European Pharmaceutical Industry
    by Franco Mariuzzo & Xiaoheng Zhang

  • 2010 External Price Benchmarking vs. Price Negotiation for Pharmaceuticals
    by Philipp Ackermann

  • 2010 The Study Of Biochemical Parameters For Naval Academy Team In The Naval Pentathlon
    by Virgil ENE-VOICULESCU & Carmen ENE-VOICULESCU

  • 2010 Diversity in firms’ innovation strategies and activities: Main findings of interviews and implications in the context of the Hungarian national
    by Havas, Attila

  • 2010 Trade and Innovation: Report on the Chemicals Sector
    by Nobuo Kiriyama

  • 2010 Margins and Market Shares:Pharmacy Incentives for Generic Substitution
    by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume

  • 2010 Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation
    by Ernst R. Berndt & Murray L. Aitken

  • 2010 Pricing and Reimbursement in U.S. Pharmaceutical Markets
    by Ernst R. Berndt & Joseph P. Newhouse

  • 2010 Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
    by Mark Trusheim & Murray L. Aitken & Ernst R. Berndt

  • 2010 Has medical innovation reduced cancer mortality?
    by Frank R. Lichtenberg

  • 2010 Success in Pharmaceutical Research: The Changing Role of Scale and Scope Economies, Spillovers and Competition
    by Tatiana Plotnikova

  • 2010 Productivity and Heterogeneous Knowledge: Exploring the Relationship in a Sample of Drug Developers
    by Giulio Bottazzi & Tatiana Plotnikova

  • 2010 Inferring the Effects of Vertical Integration from Entry Games : An Analysis of the Generic Pharmaceutical Industry
    by Kubo, Kensuke

  • 2010 The More You Spend, the More You Get? The Effects of R&D and Capital Expenditures on the Patenting Activities of Biotechnology Firms
    by Roberta Piergiovanni & Enrico Santarelli

  • 2010 R&D Portfolios and Pharmaceutical Licensing
    by Junichi Nishimura & Yosuke Okada

  • 2010 Margins and Market Shares: Pharmacy Incentives for Generic Substitution
    by Brekke, Kurt Richard & Holmås, Tor Helge & Straume, Odd Rune

  • 2010 The Battle for Patent Rights in Plant Biotechnology: Evidence from Opposition
    by Schneider, Cédric

  • 2010 Pricing and Reimbursement in U.S. Pharmaceutical Markets
    by Berndt, Ernst R. & Newhouse, Joseph P.

  • 2010 Political contributions to influence consumers: the example of the u.s. drug reimportation debate
    by Anne Boring

  • 2010 A History-Friendly Model of the Evolution of the Pharmaceutical Industry: Technological Regimes and Demand Structure
    by Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni

  • 2010 Competition in the Pharmaceutical Industry: How do Quality Differences Shape Advertising Strategies?
    by de Frutos, Maria-Angeles & Ornaghi, Carmine & Siotis, Georges

  • 2010 Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment
    by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume

  • 2010 Longitudinal Analysis of Generic Substitution
    by Dag Morten Dalen & Marilena Locatelli & Steinar Strøm

  • 2010 The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France
    by Frank Lichtenberg

  • 2010 Alfred Marshall Lecture Intellectual Property Rights Protection in Developing Countries: The Case of Pharmaceuticals
    by Pinelopi Koujianou Goldberg

  • 2010 Risk and Risk Management in Chemical Industry
    by Sanda VISAN

  • 2010 The current biotechnology outlook in Malaysia
    by Khairiah Salwa MOKHTAR & Ravi MAHALINGAM

  • 2010 On the impact of trust on consumer willingness to purchase GM food:Evidence from a European survey
    by Damien Rousselière & Samira Rousselière

  • 2010 Application Of Solid-State Fermentation For Cellulase Enzyme Production Using Trichoderma Viride
    by KIRO MOJSOV

  • 2010 Reliability Assessment And Measures For Resource-Saving In Water Lifting Engine Systems In Uzbekistan
    by OLEG GLOVATSKY & RUSTAM ERGASHEV & BAKHTIER URALOV & HOLMATZHAN ISAKOV

  • 2010 The Effects Of Inorganic Salts On Biosynthesis Of Pectinolytic Enzymes By Aspergillus Niger
    by KIRO MOJSOV &

  • 2010 305 Economists Called to Answer Questionnaire on the Pre-Market Approval of Drugs and Devices
    by Daniel B. Klein & Jason Briggeman

  • 2010 Germany's Struggle with Prices for Patent-protected Drugs
    by Mathias Kifmann & Sven Neelsen

  • 2010 The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation
    by Guy David & Sara Markowitz & Seth Richards-Shubik

  • 2010 Modern Medicine and the Twentieth Century Decline in Mortality: Evidence on the Impact of Sulfa Drugs
    by Seema Jayachandran & Adriana Lleras-Muney & Kimberly V. Smith

  • 2010 Network Effects in Biology R&D
    by Joachim Henkel & Stephen M. Maurer

  • 2010 Computer Mediated Transactions
    by Hal R. Varian

  • 2010 The Effect of Medicare Part D on Pharmaceutical Prices and Utilization
    by Mark Duggan & Fiona Scott Morton

  • 2010 Price Indexes, Inequality, and the Measurement of World Poverty
    by Angus Deaton

  • 2010 Contractibility and the Design of Research Agreements
    by Josh Lerner & Ulrike Malmendier

  • 2010(XX) Current Perspectives and Challenges of Biofuel Production and Consumption
    by VICTOR PLATON & SIMONA FRONE & ANDREEA CONSTANTINESCU & SORINA JURIST

  • 2009 Does Increased Price Competition Affect Entry of New Pharmaceutical Products?
    by Granlund, David & Rudholm, Niklas

  • 2009 Price and welfare effects of a pharmaceutical substitution reform
    by Granlund, David

  • 2009 Submarket Dynamics and Innovation: The Case of the U.S. Tire Industry
    by Guido Buenstorf & Steven Klepper

  • 2009 ¿A quién beneficia el comercio paralelo de medicamentos en la Unión Europea?
    by Costa-Font, Joan & Kanavos, Panos

  • 2009 Patenting activity in biotechnology and pharmaceuticals: a comparative analysis of the Nordic Countries
    by Enrico Sorisio

  • 2009 How variable is labor input in the Italian manufacturing: the case of the pharmaceutical industry
    by Lorenzo Carbonari

  • 2009 Of Patents and Property
    by James Bessen & Michael J. Meurer

  • 2009 Acceptance of biotechnology and social-cultural implications in Ghana
    by Quaye, Wilhemina & Yawson, Ivy & Yawson, Robert M. & Williams, Irene E.

  • 2009 The U.S. Seed Industustustry: An Exploration of Statistics Highlighting the Economic Cctivity of the U.S. Row Crop Seed Industry
    by Maud Roucan-Kane & Allan Gray

  • 2009 Investments in Pharmaceuticals Before and After TRIPS
    by Margaret Kyle & Anita McGahan

  • 2009 Technology, Competition and the Time of Entry: Diversification Patterns in the Development of New Drugs
    by Tatiana Plotnikova

  • 2009 Technological Diversity and Future Product Diversity in the Drug Industry
    by Uwe Cantner & Tatiana Plotnikova

  • 2009 Evolution 1998-2002 of the antidepressant consumption in France, Germany and the United Kingdom
    by Nathalie Grandfils & Catherine Sermet

  • 2009 What’s on the Table? The Doha Round as of August 2009
    by Matthew Adler & Claire Brunel & Gary Clyde Hufbauer & Jeffrey J. Schott

  • 2009 Surgimiento de actividades de exportación exitosas en México: tres casos específicos
    by Edgar Aragon & Anne Fouquet & Marcia Campos

  • 2009 Surgimiento de actividades de exportación exitosas en Uruguay: cuatro casos específicos
    by Michele Snoeck & Lucia Pittaluga & Hector Pastori & Rosario Domingo & Carlos Casacuberta

  • 2009 The Emergence of Successful Export Activities in Uruguay: Four Case Studies
    by Michele Snoeck & Lucia Pittaluga & Hector Pastori & Rosario Domingo & Carlos Casacuberta

  • 2009 Surgimiento de nuevas actividades de exportación en América Latina: el caso de Chile
    by Manuel Agosin & Claudio Bravo-Ortega

  • 2009 The Emergence of New Successful Export Activities in Latin America: The Case of Chile
    by Manuel Agosin & Claudio Bravo-Ortega

  • 2009 The Emergence of Successful Export Activities in Mexico: Three Case Studies
    by Edgar Aragon & Anne Fouquet & Marcia Campos

  • 2009 The Emergence of Successful Export Activities in Mexico: Three Case Studies
    by Edgar Aragón & Anne Fouquet & Marcia Campos

  • 2009 The Emergence of Successful Export Activities in Uruguay: Four Case Studies
    by Carlos Casacuberta & Rosario Domingo & Lucía Pittaluga & Héctor Pastori

  • 2009 The Emergence of New Successful Export Activities in Latin America: The Case of Chile
    by Manuel R. Agosin & Claudio Bravo Ortega

  • 2009 Price and welfare effects of a pharmaceutical substitution reform
    by Granlund, David

  • 2009 Finance and Industrial Dynamics (In French)
    by Claude DUPUY (GREThA UMR CNRS 5113) & Matthieu MONTALBAN (GREThA UMR CNRS 5113) & Sylvain MOURA (GREThA UMR CNRS 5113)

  • 2009 How financialisation shapes productive models in pharmaceutical industry: the domination and contradictions of the blockbuster conception of control (In French)
    by Matthieu MONTALBAN ( (GREThA UMR CNRS 5113)

  • 2009 How financialisation shapes productive models in pharmaceutical industry: the domination and contradictions of the blockbuster conception of control (In French)
    by Matthieu MONTALBAN (GREThA-GRES)

  • 2009 Entry in the ADHD drugs market: Welfare impact of generics and me-toos
    by Farasat A.S. Bokhari & Gary M. Fournier

  • 2009 An Analysis of the Pricing of Traits in the U.S. Corn Seed Market
    by Shi, Guanming & Chavas, Jean-Paul & Steigert, Kyle

  • 2009 An Analysis of Bundle Pricing in Horizontal and Vertical Markets: The Case of the U.S. Cottonseed Market
    by Shi, Guanming & Stiegert, Kyle & Chavas, Jean-Paul

  • 2009 On Pricing and Vertical Organization of Differentiated Products
    by Shi, Guanming & Chavas, Jean-Paul

  • 2009 Ventajas competitivas basadas en la gestión del conocimiento: El caso de tres sectores industriales del departamento del Atlántico
    by José Luis Ramos R. & Rubén Darío Rangel R.

  • 2009 La `dominancia´ alimentaria de la política monetaria, biotecnología y política de tierras
    by Carlos Gustavo Cano

  • 2009 Impact de la réforme de l’assurance maladie en Tunisie sur l’offre et la demande des médicaments
    by Ayadi, Inès

  • 2009 Biofuels: Players and discussions in Latin America
    by Mariana Saidón

  • 2009 Innovation Co-Operation Modes In Hungarian Chemical Industry
    by BEATRIX LANYI

  • 2009 An Alternative Patent Mechanism for Pharmaceutical Drugs for Tropical Diseases
    by Abdulkadir Civan

  • 2009 Small is beautiful: deutsche Chemieunternehmen schrumpfen sich produktiv
    by Oleg Badunenko

  • 2009 R&D offshoring and clustering dynamics in pharmaceuticals and biotechnology: key features and insights from the Chinese case
    by Abdelillah Hamdouch & Feng He

  • 2009 The Effect of GDP Growth on Pharmaceutical Patent Protection, 1945-2005
    by Summer La Croix & Ming Liu

  • 2008 Internationalising to create Firm Specific Advantages: Leapfrogging strategies of U.S. Pharmaceutical firms in the 1930s and 1940s & Indian Pharmaceutical firms in the 1990s and 2000s
    by Athreye, Suma & Godley, Andrew

  • 2008 Experimentation with Strategy and the Evolution of Dynamic Capability in the Indian Pharmaceutical Sector
    by Athreye, Suma & Kale, Dinar & Ramani, Shyama V.

  • 2008 New Europe's Promise for Life Sciences
    by Filippov, Sergey & Kalotay, Kalman

  • 2008 Facing the Trial of Internationalizing Clinical Trials to Developing Countries: Some Evidence from Mexico
    by Santiago-Rodriguez, Fernando

  • 2008 On the Effects of Suggested Prices in Gasoline Markets
    by Riemer P. Faber & Maarten C.W. Janssen

  • 2008 Pharmaceutical Research Strategies
    by Sandra Phlippen & An Vermeersch

  • 2008 The Tunisian Pharmaceutical Sector in Transformation: Inventory of Fixtures and Innovation Prospects
    by Nejla Yacoub

  • 2008 Stratégies d’innovation des firmes des sciences de la vie et appropriation des ressources végétales : processus et enjeux Innovations strategies of firms in life science and appropriation of vegetal resources : process and stakes
    by Blandine Laperche

  • 2008 La lutte anti-blanchiment dans le secteur de l’assurance (the fight against money laundering in the insurance sector)
    by Éric Vernier & Hubert Delval

  • 2008 Consumer Learning and Heterogeneity: Dynamics of Demand for Prescription Drugs after Patent Expiration
    by Ching, Andrew

  • 2008 Policy options of agricultural biotechnology R&D in Sub-Saharan Africa: key issues and aspects
    by Yawson, Robert M. & Yawson, Ivy

  • 2008 Firm dynamic governance of global innovation by means of flexible networks of connections
    by Gay, Brigitte

  • 2008 Overcoming Innovation Limits through Outward FDI: The Overseas Acquisition Strategy of Indian Pharmaceutical Firms
    by Pradhan, Jaya Prakash

  • 2008 Regulation, generic competition and pharmaceutical prices: Theory and evidence from a natural experiment
    by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume

  • 2008 Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy
    by Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari

  • 2008 Effects of Regulation on Drug Launch and Pricing in Interdependent Markets
    by Patricia M. Danzon & Andrew J. Epstein

  • 2008 Drug price setting and regulation in France
    by Nathalie Grandfils

  • 2008 Home to Market: Response,Resurgence and Transformation of Ayurveda from 1830's to 1920
    by M.S. Harilal

  • 2008 Genetic Codes of Mergers, Post Merger Technology Evolution and Why Mergers Fail
    by Alexander Cuntz

  • 2008 Generic Substitution
    by Furu, Kari & Dalen, Dag Morten & Locatelli, Marilena & Strøm, Steinar

  • 2008 Multinationals in the Knowledge Economy - a case study of AstraZeneca in Sweden
    by Andersson, Martin & Johansson, Börje & Karlsson, Charlie & Lööf, Hans

  • 2008 The European Socio-Economic Models of a Knowledge-based society. \r\nMain findings and conclusion \r\n
    by Bruno AMABLE (Université Paris I and CEPREMAP) & Yannick LUNG (GREThA UMR CNRS 5113 and GERPISA)

  • 2008 The European Socio-Economic Models of a Knowledge-based society. Main findings and conclusions
    by Bruno AMABLE (Université Paris I and CEPREMAP) & Yannick LUNG (GREThA-GRES)

  • 2008 Intellectual property rights in agricultural and agro-food biotechnologies to 2030 (© OECD International Futures Programme)
    by Trommetter, M.

  • 2008 External referencing and pharmaceutical price negotiation
    by Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella

  • 2008 Innovation in India and China : Challenges and Prospects in Pharmaceuticals and Biotechnology
    by Jayan Jose Thomas

  • 2008 Growing the Opportunities for Bioscience Entrepreneurship in Asia
    by Paul S. Teng

  • 2008 Biotechnology Crops (Genetically Modified Plants)
    by Paul S. Teng

  • 2008 Biodetection — Diagnosing Plant Diseases and Detecting Genetically Modified Food
    by Paul S. Teng

  • 2008 Bioremediation
    by Paul S. Teng

  • 2008 Biofuels
    by Paul S. Teng

  • 2008 Mushroom Culture as a Bioscience Enterprise
    by Paul S. Teng

  • 2008 Biofermentation, Biofertilizers and Biopesticides
    by Paul S. Teng

  • 2008 Tissue Culture as a Bioscience Enterprise
    by Paul S. Teng

  • 2008 Hybrid Plant and Seed Varieties
    by Paul S. Teng

  • 2008 Exploiting Developments in Science for New Bioscience Enterprises
    by Paul S. Teng

  • 2008 Bioscience Entrepreneurship in Asia:Creating Value with Biology
    by Paul S Teng

  • 2008 Stratégies de R et D et innovation dans l’industrie pharmaceutique en France : une étude économétrique sur données individuelles
    by Zouikri, Messaoud

  • 2008 A hybrid methodology for the Cox proportional hazard model
    by Marianela Luzardo Briceño

  • 2008 Geographic and Temporal Heterogeneity in Public Prescription Pharmaceutical Expenditures in Spain
    by Lauridsen, Jorgen & Bech, Mickael & Lopez, Fernando & Mate Sanchez, Mariluz

  • 2008 Selbstselektion statt Personalauswahl? Auslandsentsendungen in der deutschen chemischen Industrie
    by Heiner Minssen & Susanne Schmidt

  • 2008 The Determinants of Capital Structure of the Chemical Industry in Pakistan
    by Muhammad Rafiq & Asif Iqbal & Muhammad Atiq

  • 2008 Critical Success Factors for Intra-Disciplinary Transformation of the Agricultural Biotechnology Industry in Taiwan based on the Value Chain Concept
    by Meng-Shiunn Lee

  • 2008 Course technologique et valeur boursière. Une étude d'événements basée sur l'industrie pharmaceutique
    by Sandy Campart & Étienne Pfister

  • 2007 Consumer Information and Pharmaceutical Prices: Theory and Evidence
    by Granlund, David & Rudholm, Niklas

  • 2007 Exploring the relationship between scientist human capital and firm performance: The case of biomedical academic entrepreneurs in the SBIR program
    by Czarnitzki, Dirk & Toole, Andrew A.

  • 2007 Restructuring of Energy-intensive Industrial Branches in Romania and Proposals for Industrial Policy Measures
    by Edward Christie & Gabor Hunya & Waltraut Urban

  • 2007 Generic entry into a regulated pharmaceutical market
    by Iván Moreno Torres & Jaume Puig & Joan-Ramon Borrell-Arqué

  • 2007 Multimarket contact in pharmaceutical markets
    by Javier Coronado & Sergi Jiménez-Martín & Pedro L. Marín

  • 2007 The determinants of pricing in pharmaceuticals: Are U.S. prices really higher than those of Canada?
    by Antonio Cabrales & Sergi Jiménez-Martín

  • 2007 Generic entry into a regulated pharmaceutical market
    by Iván Moreno Torres & Jaume Puig & Joan-Ramon Borrell-Arqué

  • 2007 Brevet, innovation modulaire et collaboration : Le cas des vaccins géniques
    by Antoine Bureth & Moritz Mueller & Julien Pénin & Sandrine Wolff

  • 2007 The Emergence of new Successful Export Activities in Uruguay
    by Michele Snoeck & Carlos Casacuberta & Rosario Domingo & Héctor Pastori & Lucía Pittaluga

  • 2007 Simulaatio lääkekehitysalan kannattavuudesta ja riskeistä
    by Hermans, Raine & Kulvik, Martti

  • 2007 Imposing a unilateral carbon constraint on European energy-intensive industries and its impact on their international competitiveness - data & analysis
    by Bergmann, Manfred & Schmitz, Andreas & Hayden, Mark & Kosonen, Katri

  • 2007 Betweenness Centrality of Fractal and Non-Fractal Scale-Free Model Networks and Tests on Real Networks
    by Kitsak, Maksim & Havlin, Shlomo & Paul, Gerald & Riccaboni, Massimo & Pammolli, Fabio & Stanley, H. Eugene

  • 2007 Financial Risk in the Biotechnology Industry
    by Joseph H. Golec & John A. Vernon

  • 2007 Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration
    by Glenn Ellison & Sara Fisher Ellison

  • 2007 Effects of 'Authorized-Generics' on Canadian Drug Prices
    by Paul Grootendorst

  • 2007 The Relationship among innovative Output, Productivity, and Profitability. A test comparing USPTO and EPO data
    by Enrico Santarelli & Francesca Lotti

  • 2007 Economic Policy in Health Care: Sickness Absence and Pharmaceutical Cost
    by Granlund, David

  • 2007 Consumer Information and Pharmaceutical Prices: Theory and Evidence
    by Granlund, David & Rudholm, Niklas

  • 2007 Incrementalism of environmental innovations versus paradigmatic change: A comparative study of the automotive and chemical industries
    by Vanessa OLTRA (GREThA) & Maïder SAINT JEAN (GREThA)

  • 2007 Incrementalism of environmental innovations versus paradigmatic change: A comparative study of the automotive and chemical industries
    by Vanessa OLTRA (GREThA-GRES) & Maïder SAINT JEAN (GREThA-GRES)

  • 2007 Flexibility in the implementation of intellectual property rights in agricultural biotechnology
    by Trommetter, M.

  • 2007 Indian Innovation Systems and Emergence of Biopharmaceutical Sector : Issues and Prospects
    by Sachin Chaturvedi

  • 2007 Downsizing in German Chemical Manufacturing Industry during the 1990s: Why Small Is Beautiful?
    by Oleg Badunenko

  • 2007 Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?
    by Kurt R. Brekke & Astrid L. Grasdal & Tor Helge Holmås

  • 2007 The Determinants of Pricing in Pharmaceuticals: Are U.S. prices really higher than those of Canada?
    by Antonio Cabrales & Sergi Jiménez-Martín

  • 2007 Multimarket Contact in Pharmaceutical Markets
    by Javier Coronado & Sergi Jiménez-Martín & Pedro L Marín

  • 2007 Multimarket Contact in Pharmaceutical Markets
    by Javier Coronado & Sergi Jiménez-Martín & Pedro L. Marín

  • 2007 The Determinants of Pricing in Pharmaceuticals: Are U.S. Prices Really Higher than Those of Canada?
    by Antonio Cabrales & Sergi Jiménez-Martín

  • 2007 Positionierung der deutschen Industrie im globalen Konsolidierungsprozess : im Auftrag des Bundesministeriums für Wirtschaft und Technologie
    by Michael Reinhard & Hans Schedl & Achim Buchwald & Ralph Henger

  • 2007 What is "Business Development"? - The Case of Biotechnology
    by Sonja Kind & Dodo zu Knyphausen-Aufseß

  • 2007 Modular Innovations and Distributed Processes. The Case of Genetically Engineered Vaccines
    by Bureth, Antoine & Pénin, Julien

  • 2007 Managing the Uneven Evolution of Know-How. Engineering Design as "Social technology"
    by Brusoni, Stefano

  • 2007 Testing price-fixing agreements in a multimarket context: The European case of vitamin C
    by Balaguer, Jacint & Orts, Vicente & Uriel, Ezequiel

  • 2007 Les déterminants des fusions-acquisitions. Le cas de l'industrie pharmaceutique
    by Gautier Duflos & Étienne Pfister

  • 2006 Allocative efficiency measurement revisited: do we really need input prices?
    by Badunenko, Oleg & Fritsch, Michael & Stephan, Andreas

  • 2006 Jüngere Entwicklungen auf dem Risikokapitalmarkt für Biotechnologie in Deutschland
    by Schudy, Simeon

  • 2006 Überwindung betriebswirtschaftlicher Defizite im Innoregio-Netzwerk Kunststoffzentrum Westmecklenburg
    by Neunteufel, Herbert & Rössel, Gottfried & Sassenberg, Uwe & Laske, Michael & Kipura, Janine & Brüning, Andreas

  • 2006 Allocative efficiency measurement revisited: Do we really need input prices?
    by Badunenko, Oleg & Fritsch, Michael & Stephan, Andreas

  • 2006 Indian Pharma Within Global Reach?
    by Gehl Sampath, Padmashree

  • 2006 Rough Road to Market: Institutional Barriers to Innovations in Africa
    by Oyelaran-Oyeyinka, Banji & Gehl Sampath, Padmashree

  • 2006 India's product patent protection regime: Less or more of "pills for the poor"?
    by Gehl Sampath, Padmashree

  • 2006 The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan
    by Mahlich, Jörg C. & Roediger-Schluga, Thomas

  • 2006 Breaking the Fence: Patent Rights and Biomedical Innovation in 'Technology Followers'
    by Gehl Sampath, Padmashree

  • 2006 Knowledge-sourcing strategies for cross-disciplinarity in bionanotechnology
    by Isamel Rafols & Martin Meyer

  • 2006 Riskirahoituksen merkitys biotekniikka-alalla: Pääomasijoittajien vertailu yritysten näkökulmasta
    by Luukkonen, Terttu & Maunula, Mari

  • 2006 Adaption of New Technologies and Costs of Health Care
    by Kulvik, Martti & Linnosmaa, Ismo & Hermans, Raine

  • 2006 Coaching Small Biotech Companies into Success: The Value-adding Function of VC
    by Terttu Luukkonen, & Mari Maunula,

  • 2006 The Perceived Value-added of Venture Capital Investors. Evidence from Finnish Biotechnology Industry
    by Maunula, Mari

  • 2006 Helsingin seudun klusterit sekä erikoistuminen bioteknologiaan ja logistiikkaan
    by Hernesniemi, Hannu & Kulvik, Martti

  • 2006 Private Sector R&D in the New Member States: Hungary
    by Havas, Attila

  • 2006 A Generalized Preferential Attachment Model for Business Firms Growth Rates: I. Empirical Evidence
    by Pammolli, Fabio & Fu, Dongfeng & Buldyrev, Sergey V. & Riccaboni, Massimo & Matia, Kaushik & Yamasaki, Kazuko & Stanley, H. Eugene

  • 2006 A Generalized Preferential Attachment Model for Business Firms Growth Rates: II. Mathematical Treatment
    by Buldyrev, Sergey V. & Pammolli, Fabio & Riccaboni, Massimo & Yamasaki, Kazuko & Fu, Dongfeng & Matia, Kaushik & Stanley, H. Eugene

  • 2006 Global Competitiveness of Indian Pharmaceutical Industry: Trends and Strategies
    by Pradhan, Jaya Prakash

  • 2006 Overseas Acquisition versus Greenfield Foreign Investment: Which Internationalization Strategy is better for Indian Pharmaceutical Enterprises?
    by Pradhan, Jaya Prakash & Alakshendra, Abhinav

  • 2006 Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research
    by Jeffrey L. Furman & Margaret K. Kyle & Iain M. Cockburn & Rebecca Henderson

  • 2006 Openness and Industrial Responses in a Wal-Mart World: A Case Study of Mexican Soaps, Detergents and Surfactant Producers
    by Beata Smarzynska Javorcik & Wolfgang Keller & James R. Tybout

  • 2006 Did Medicare Induce Pharmaceutical Innovation?
    by Daron Acemoglu & David Cutler & Amy Finkelstein & Joshua Linn

  • 2006 R&D in the Belgian Pharmaceutical Sector
    by Helga De Doncker

  • 2006 Jüngere Entwicklungen auf dem Risikokapitalmarkt für Biotechnologie in Deutschland
    by Simeon Schudy

  • 2006 Indian Patent Policy and Publich Health : implications from the Japanese Experience
    by Aoki, Reiko & Kubo, Kensuke & Yamane, Hiroko

  • 2006 The Pharmacia Story of Entrepreneurship and as a Creative Technical University - An Experiment in Innovation, Organizational Break Up and Industrial Renaissance
    by Eliasson, Gunnar & Eliasson, Åsa

  • 2006 Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?
    by Brekke, Kurt R. & Grasdal, Astrid L. & Holmås, Tor Helge

  • 2006 FDI and Spillover Effects in the Indian Pharmaceutical Industry
    by Annika Bergman

  • 2006 Allocative Efficiency Measurement Revisited: Do We Really Need Input Prices?
    by Oleg Badunenko & Michael Fritsch & Andreas Stephan

  • 2006 The Dye Famine and its Aftermath: Knowledge Diffusion and Entry
    by Genesove, David

  • 2006 Estudio sobre la propiedad intelectual en el sector farmacéutico colombiano
    by Emilio J. Archila & Gabriel Carrasquilla & Marcela Meléndez & Juan Pablo Uribe

  • 2006 Estudio sobre la propiedad intelectual en el sector farmacéutico colombiano
    by Emilio Archila & Gabriel Carrasquilla & Marcela Meléndez & Juan Pablo Uribe

  • 2006 Reference Pricing of Pharmaceuticals
    by Kurt R. Brekke & Ingrid Königbauer & Odd Rune Straume

  • 2006 Research Strategies in Science-based Start-ups - Effects on performance in Danish and Swedish biotechnology
    by Finn Valentin & Henrich Dahlgren & Rasmus Lund Jensen

  • 2006 La propriété intellectuelle dans les biotechnologies agricoles : quels enjeux pour quelles perspectives ?
    by Michel Trommetter

  • 2006 Comment favoriser l'innovation dans le secteur pharmaceutique : brevets et/ou récompenses ?
    by Paul Belleflamme & Tanguy van Ypersele

  • 2006 Intégration technologique et valeur boursière des firmes de biotechnologies
    by Lionel Nesta & Pier-Paolo Saviotti

  • 2006 Biotechnologies et industrie pharmaceutique. Un modèle évolutionnaire conforme à l'histoire
    by Franco Malerba & Luigi Orsenigo & Sandrine Selosse

  • 2006 On the Life Cycle of Knowledge Intensive Sectors
    by Thomas Grebel & Jackie Krafft & Pier-Paolo Saviotti

  • 2006 The Evolution of Geographic Structure in New Industries
    by Steven Klepper

  • 2005 Does Public Scientific Research Complement Industry R&D Investment? The Case of NIH Supported Basic and Clinical Research and Pharmaceutical Industry R&D
    by Toole, Andrew A.

  • 2005 Public R&D Policy: The Right Turns of the Wrong Screw? The Case of the German Biotechnology Industry
    by Fier, Andreas & Heneric, Oliver

  • 2005 Functional Foods In The European Union: An Overview Of The Sector'S Main Issues
    by Alessandra CASTELLINI & Maurizio Canavari & Carlo Pirazzoli

  • 2005 Production of a New Drug: A Sequential Investment ProcessUnder Uncertainty
    by Marcello Basili & Roberto Renò & Carlo Zappia

  • 2005 Technological Characteristics and R&D Alliance Form: Evidence from the U.S. Biotechnology Industry
    by Xia Wang

  • 2005 Phases of Imitation and Innovation in a North-South Endogenous Growth Model
    by Daniel Rais & Jonathan Goldman

  • 2005 “Branded Generics” As A Strategy To Limit Cannibalization Of Pharmaceutical Markets
    by Michael R. Ward & David Reiffen

  • 2005 Innovation Paths of Estonian Biotechnology
    by Tınis Mets

  • 2005 Empirical Tests of Optimal Cognitive Distance
    by Wuyts, S.H.K. & Colombo, M. & Dutta, S. & Nooteboom, B.

  • 2005 Density and Strength of Ties in Innovation Networks : An Analysis of Multi-Media and Biotechnology
    by Gilsing, V.A. & Nooteboom, B.

  • 2005 Consequences of the IPPC-directive's BAT requirements for abatement costs and emissions
    by Jan Larsson & Kjetil Telle

  • 2005 The Growth of Business Firms: Theoretical Framework and Empirical Evidence
    by Fu, Dongfeng & Pammolli, Fabio & Buldyrev, Sergey V. & Riccaboni, Massimo & Matia, Kaushik & Yamasaki, Kazuko & Stanley, H. Eugene

  • 2005 Trips and Patenting Activity: Evidence from the Indian Pharmaceutical Industry
    by Alka Chadha

  • 2005 Product cycles, innovation and exports: A study of Indian pharmaceuticals
    by Alka Chadha

  • 2005 Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending
    by Joseph Golec & Shantaram Hegde & John A. Vernon

  • 2005 Socio-economic Impact of Nanoscale Science: Initial Results and NanoBank
    by Lynne G. Zucker & Michael R. Darby

  • 2005 Parallel Imports, Drag Price Control and Pharmaceutical Innovation
    by Ken Tabata & Testuya Shinkai & Satoru Tanaka & Makoto Okamura

  • 2005 Who Develops Innovations in Medicine for the Poor? Trends in Patent Applications Related to Medicines for HIV/AIDS, Tuberculosis, Malaria and Neglected Diseases
    by Ito, Banri & Yamagata, Tatsufumi

  • 2005 Testing Collusive Prices In A Multimarket Context: The European Case Of Vitamin C
    by Jacint Balaguer & Ezequiel Uriel Jiménez & Vicente Orts

  • 2005 Reference Pricing of Pharmaceuticals
    by Brekke, Kurt R & Königbauer, Ingrid & Straume, Odd Rune

  • 2005 Start-ups, firm growth and the consolidation of the French biotech industry
    by Avenel, E. & Corolleur, F. & Gauthier, C. & Rieu, C.

  • 2005 Knowledge and Productivity in the World's Largest Manufacturing Corporations Level:Panel Data analysis on Compustat and Patent data
    by Lionel Nesta

  • 2005 Biosafety Protocol, International Trade and Agricultural Biotechnology : Policy Inferences for India
    by Sachin Chaturvedi & Lian Chawii

  • 2005 State of Competition in the Wholesale and Retail Sector
    by Ma. Teresa Dueñas-Caparas

  • 2005 Generic Drug Industry Dynamics
    by David Reiffen & Michael R. Ward

  • 2005 Strategic Reasons for Patenting: Between Exclusion and Coordination Rationales
    by Antoine Bureth & Rachel Levy & Julien Pénin & Sandrine Wolff

  • 2004 Price Regulation and Competition in Japanese Pharmaceutical Market
    by Tomofumi & Anegawa

  • 2004 Biotechnology in New Zealand
    by Dan Marsh

  • 2004 Biotechnology in New Zealand
    by Dan Marsh

  • 2004 Regulatory ambivalence and the limitations of pharmaceutical policy in Spain
    by Joan Costa & Jaume Puig

  • 2004 Regulatory ambivalence and the limitations of pharmaceutical policy in Spain
    by Joan Costa & Jaume Puig

  • 2004 Estudios de competitividad sectoriales. Industria manufacturera
    by María Inés Terra & Gustavo Bittencourt & Rosario Domingo & Carmen Estrades & Gabriel Katz & Alvaro Ons & Héctor Pastori

  • 2004 Optimal Intellectual Property Rights Protection and Humanitarian Assistance during and International Health Emergency
    by Drusilla K. Brown & George Norman

  • 2004 Persistent Knowledge Specialisation and Intra-Industry Heterogeneity: an Analysis of the Spanish Pharmaceutical Industry
    by Pablo D'Este Cukierman

  • 2004 FDI spillovers and local productivity growth: evidence from Indian pharmaceutical industry
    by Pradhan, Jaya Prakash

  • 2004 Market Structure and Drug Innovation
    by Pammolli, Fabio & Riccaboni, Massimo

  • 2004 Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure
    by Magazzini, Laura & Pammolli, Fabio & Riccaboni, Massimo

  • 2004 Preferential attachment and growth dynamics in complex systems
    by Yamasaki, Kazuko & Matia, Kaushik & Buldyrev, Sergey V. & Fu, Dongfeng & Pammolli, Fabio & Riccaboni, Massimo & Stanley, H. Eugene

  • 2004 The Effect of Drug Vintage on Survival: Micro Evidence from Puerto Rico's Medicaid Program
    by Frank R. Lichtenberg

  • 2004 Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
    by Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson & Matthew W. Strobeck

  • 2004 Vertical Product Differentiation, Market Entry, and Welfare
    by Reisinger, Markus

  • 2004 Competence in Health Care - An Industrial Systems Analysis Using Competence Bloc Theory to Compare European and US Health Care
    by Eliasson, Gunnar & Eliasson, Åsa

  • 2004 The Norwegian market for pharmaceuticals and the non-mandatory substitution reform of 2001: the case of enalapril
    by Razzolini, Tiziano

  • 2004 The Origin and Location of Entrants in the Evolution of the U.S. Tire Industry
    by G. Buenstorf & S. Klepper

  • 2004 A Dynamic Oligopoly Structural Model for the Prescription Drug Market After Patent Expiration
    by Andrew Ching

  • 2004 Las patentes aceleran o retrasan la comercializacion de nuevos medicamentos en los paises en desarrollo?
    by Joan Ramon Borrell Arque

  • 2004 Price Competition in Pharmaceuticals: The Case of Anti-infectives
    by Steven N. Wiggins & Robert Maness

  • 2004 La gouvernance des jeunes entreprises innovantes:un éclairage analytique à partir du cas des sociétés de biotechnologies
    by Marc-Hubert Depret & Abdelillah Hamdouch

  • 2004 L'interaction des dynamiques individuelles et collectives dans le processus de développement territorial
    by Sophie-Hélène Bataïni

  • 2003 Die Bedeutung von Patentschutz für den Technologietransfer in Entwicklungsländer : Erfahrungen der chemischen Industrie in Südkorea, Malaysia und Chile im Vergleich
    by Thomas Röhm

  • 2003 Das Marketingniveau in der Kunststoffbranche Westmecklenburgs
    by Neunteufel, Herbert & Rössel, Gottfried & Sassenberg, Uwe

  • 2003 International Price-Fixing Cartels and Developing Countries: A Discussion of Effects and Policy Remedies
    by Margaret Levenstein & Valerie Suslow & Lynda Oswald

  • 2003 Pharmaceutical generics, vertical product differentiation and public policy
    by Antonio Cabrales

  • 2003 Pharmaceutical generics, vertical product differentiation and public policy
    by Antonio Cabrales

  • 2003 Optimal Intellectual Property Rights Exhaustion and Humanitarian Assistance during a National Health Emergency
    by Drusilla K. Brown & George Norman

  • 2003 The Knowledge Bases of the World's Largest Pharmaceuticals Groups: what do Patent Citations to Non-Patent Literature Reveal?
    by Stefano Brusoni & Paola Criscuolo & Aldo Geuna

  • 2003 Intangible Assests and Market Value: Evidence from Biotechnology Firms
    by Lionel Nesta & Pier-Paolo Saviotti

  • 2003 Reverse Technology Transfer: A Patent Citation Analysis of the European Chemical and Pharmaceutical Sectors
    by Paola Criscuolo

  • 2003 The Effects of Environmental Regulation On Technology Diffusion: The Case of Chlorine Manufacturing
    by Stavins, Robert & Snyder, Lori & Miller, Nolan

  • 2003 The economic impact of Biotechnology in New England
    by Allen, Thomas & Gabe, Todd

  • 2003 Liberalization, Firm Size and R&D performance: A Firm Level Study of Indian Pharmaceutical Industry
    by Pradhan, Jaya Prakash

  • 2003 On Size and Growth of Business Firms
    by De Fabritiis, Gianni & Riccaboni, Massimo & Pammolli, Fabio

  • 2003 TRIPS and the Pharmaceutical Industry in Bangladesh: Towards a National Strategy
    by Professor Tony VanDuzer

  • 2003 Pharmaceutical Use and Expenditure for Cardiovascular Disease and Stroke: A Study of 12 OECD Countries
    by Michael Dickson & Stéphane Jacobzone

  • 2003 Uncertainty in the Generic Versus Brand Name Prescription Decision
    by Hellström, Jörgen & Rudholm, Niklas

  • 2003 Titanium Implants – A Comparison of a Swedish and an Ohio Firm
    by Fridh, Ann-Charlotte

  • 2003 Direct-to-Consumer Advertising in Pharmaceutical Markets
    by Brekke, Kurt R. & Kuhn, Michael

  • 2003 The Effects of Environmental Regulation on Technology Diffusion: The Case of Chlorine Manufacturing
    by Lori Snyder & Nolan Miller & Robert Stavins

  • 2003 Globalisation and Its Impact on Competitiveness: the Case of the British and German Pharmaceutical Industry
    by Christel Lane & Jocelyn Probert

  • 2003 Pharmaceutical Generics, Vertical Product Differentiation, and Public Policy
    by Antonio Cabrales

  • 2003 Reference prices: The Spanish way
    by Jorge Mestre

  • 2002 Erfolgsabhängige Vergütung: Ein sicherer Weg zur Steigerung der Leistung von Top-Managern?
    by Zwick, Thomas & Wolf, Elke & Beblo, Miriam

  • 2002 Does New Zealand have an Innovation System for Biotechnology?
    by Dan Marsh

  • 2002 Does New Zealand have an Innovation System for Biotechnology?
    by Dan Marsh

  • 2002 Economic Insights and Deficits in European Biotechnology Patent Policy
    by Gilroy, Bernard Michael & Volpert, Tobias

  • 2002 Economic Insights and Deficits in European Biotechnology Patent Policy
    by Gilroy, Bernard Michael & Vollpert, Tobias

  • 2002 A Comparison of U.S. and European University-Industry Relations in the Life Sciences
    by Owen-Smith, Jason & Riccaboni, Massimo & Pammolli, Fabio & Powell, Walter W.

  • 2002 Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "equipment for your health"
    by Frank R. Lichtenberg & Suchin Virabhak

  • 2002 Benefits and Costs of Newer Drugs: An Update
    by Frank Lichtenberg

  • 2002 Innovation and Market Structure: An Empirical Evaluation of the 'Bounds Approach' in the Chemical Industry
    by Marín Uribe, Pedro Luis & Siotis, Georges

  • 2002 Biotecnologia: corporações, financiamento da inovação e novas formas organizacionais
    by Silveira, José Maria F. J. da

  • 2002 Los derechos sobre las patentes biotecnológicas y su repercusión económica en la Unión Europea
    by Mª Carmen Fernández Díez

  • 2002 Mercados de violencia" y guerra civil en América Latina en los 90*"
    by Javier Guerrero Barón

  • 2001 Restricciones Macroeconómicas al Desarrollo Económico y la Reducción de la Pobreza: El Caso de Bolivia
    by Schweickert, Rainer

  • 2001 Innovation et marche financiers: l'impact des avancees therapeutiques sur les rentabilites boursieres des firmes
    by Campart, S. & Pfister, E.

  • 2001 Research Incentives in Competing Markets: A Model of the Development of New Vaccines
    by Rey, P.

  • 2001 The World Trade Organization and Publicly Funded Healthcare in Canada
    by Ostry, A.

  • 2001 Buying Science, Selling Drugs
    by Evans, R.G. & Morgan, S.G. & Barer, M.L.

  • 2001 Do court-ordered breakups spur innovation?
    by Leon Taylor

  • 2001 Modern Biotechnology in New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99
    by Dan Marsh

  • 2001 Modern Biotechnology in New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99
    by Dan Marsh

  • 2001 On Firm Growth in Networks
    by Riccaboni, Massimo & Pammolli, Fabio

  • 2001 An Empirical Model of Heterogeneous Consumer Search for Retail Prescription Drugs
    by Alan T. Sorensen

  • 2001 The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey
    by Frank R. Lichtenberg

  • 2001 Global/local articulation in industrial models for phamaceuticals, automobile and aeronautics (In French)
    by Marie-Claude BÉLIS-BERGOUIGNAN (IFREDE-E3i) & Vincent FRIGANT (IFREDE-E3i) & Damien TALBOT (LEREPS)

  • 2001 The Self-Organisation of Strategic Alliances
    by Andreas Pyka & Paul Windrum

  • 2001 Innovation Networks in the Biotechnology-Based Sectors
    by Andreas Pyka & Paolo Saviotti

  • 2000 How to win Schumpeterian Competition. Technological Transfers in the German Plastics Industry from the 1930s to the 1970s
    by Streb, J.

  • 2000 How to win Schumpeterian Competition. Technological Transfers in the German Plastics Industry from the 1930s to the 1970s
    by Streb, J.

  • 2000 Heternenous Labor Demand and Aggregate Job Flows. Specification, Estimation and Testing with French Data
    by Fairise, X. & Feve, P.

  • 2000 L'utilisation des notions de confiance et de proximite dans l'etude des processus de R&D pharmaceutiques
    by Perrochon, D. & Lebert, D.

  • 2000 Coalitions industrielles, reseaux de firmes et dynamiques de concurrence-cooperation dans les secteurs en cours de globalisation : le cas de l'industrie pharmaceutique
    by Hamdouch, A. & Depret, M.-H.

  • 2000 Fostering Innovation in a Small Open Economy: The Case of the New Zealand Biotechnology Sector
    by Dan Marsh

  • 2000 Fostering Innovation in a Small Open Economy: The Case of the New Zealand Biotechnology Sector
    by Dan Marsh

  • 2000 Heterogeneity in Returns to Scale: A Random Coefficient Analysis with Unbalanced Panel Data
    by Erik Biørn & Kjersti-Gro Lindquist & Terje Skjerpen

  • 2000 The Nature and the Extent of the Market for Technology in Biopharmaceuticals
    by Arora, Ashish & Gambardella, Alfonso & Pammolli, Fabio & Riccaboni, Massimo

  • 2000 Global Competitiveness in Pharmaceuticals: A European Perspective
    by Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio

  • 2000 Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs
    by Ernst R. Berndt & Robert S. Pindyck & Pierre Azoulay

  • 2000 Entry and the Number of firms in the Swedish Pharmaceuticals Market
    by Rudholm, Niklas

  • 2000 Towards a History Friendly Model of Innovation, Market Structure and Regulation in the Dynamics of the Pharmaceutical Industry: the Age of Random Screening
    by Franco Malerba & Luigi Orsenigo

  • 2000 Corporate Governance and the Governance of Innovation: the Case of Pharmaceutical Industry
    by Nicola Lacetera

  • 2000 The determinants of pharmaceutical research and development expenditures
    by Henry Grabowski & John Vernon

  • 1999 An Examination of Technology Strategies for the Integration of Bioinformatics in Pharmaceutical R&D Processes
    by Michael M. Hopkins

  • 1999 Network Effects and Diffusion in Pharmaceutical Markets: Antiulcer Drugs
    by Ernst R. Berndt & Robert S. Pindyck & Pierre Azoulay

  • 1999 How to Win Schumpeterian Competition: Technological Transfers in the German Plastics Industry from the 1930s to the 1970s
    by Jochen Streb

  • 1999 Incidencia del régimen de patentes de la industria farmacéutica sobre la economía colombiana
    by Luis Alberto Zuleta Jaramillo & Mónica Lylián Parra Torrado

  • 1998 Demand for Prescription Drugs: The Effects of Managed Care Pharmacy Benefits
    by Rika Onishi Mortimer

  • 1998 Characterizing Informational Barriers To Entry In The Anti-Ulcer Drug Market
    by Matthew Shum

  • 1998 Random Coefficients and Unbalanced Panels: An Application on Data from Norwegian Chemical Plants
    by Erik Biørn & Kjersti-Gro Lindquist

  • 1998 International Co-operative Agreements in Hungary in the mid-1990s: Evolution, organisational forms and industry characteristics
    by Havas, Attila

  • 1998 The Introduction of Pharmaceutical Product Patents in India: "Heartless Exploitation of the Poor and Suffering"?
    by Jean O. Lanjouw

  • 1998 The Impact of Generic Competition on Brand Name Market Shares - Evidence from Micro Data
    by Aronsson, Thomas & Bergman, Mats & Rudholm, Niklas

  • 1998 The Impact of Generic Competition on Brand Name Market Shares: Evidence from Micro Data
    by Aronsson, Thomas & Bergman, Mats A. & Rudholm, Niklas

  • 1998 Evolutionary innovations: learning, entrepreneurship and the dynamics of the firm
    by Maureen McKelvey

  • 1997 Foreign Direct Investment, Technological Capabilities and Performance in the Chinese Pharmaceutical Industry
    by Steven White & Hideki Yoshihara & Xielin Liu

  • 1997 Organizational Dynamics and Strcuture in the Chinese Pharmaceutical Industry: A Technological System Perspective
    by Steven White

  • 1997 Alternative Transition Trajectories for Complementary Asset Markets in China's Pharmaceutical Industry
    by Steven White & Xielin Liu

  • 1997 Outsourcing of Research by Pharmaceutical and Biotechnology Firms
    by Tapon, F. & Thong, M.

  • 1997 The Introduction of Pharmaceutical Product Patents in India: "Heartless Exploitation of the Poor and Suffering"?
    by Lanjouw, J.O.

  • 1997 The Pharmaceutical Industry in India and Hungary. Policies, Institutions, and Technological Development
    by Felker, G. & Chaudhuri, S. & Gyorgy, K. & Goldman, M.

  • 1997 Medicinal Plants, Rescuing Global Heritage
    by Lambert, J. & Srivastava, J. & Vietmeyer, N.

  • 1997 Les prestataires logistiques et la distribution pharmaceutique. Les barrieres a l'entree: vitres blindees ou glaces sans tain
    by Mattiuzzo, N. & Le Goff, J.

  • 1997 Merger, Retionalisation and the "High Commitment" Organisation
    by Randle, K.

  • 1997 Israel: Secteur de l'equipement medical
    by Theriault, V.

  • 1997 Chili:Secteur de l'equipement medical
    by Froissart, S.

  • 1997 Belgique: Secteur de l'equipement medical haute technologie
    by Froissart, S.

  • 1997 Thailande: Secteur de l'equipement medical
    by Froissart, S.

  • 1997 Malaisie: Secteur de l'equipement medical de haute technologie
    by Froissart, S.

  • 1997 Economic consequences of the German environmental liability act: Capital market response for the chemical industry
    by Bartsch, Elga

  • 1997 The Strategic Response by Pharmaceutical Firms to the Medicaid Most-Favored-Customer Rules
    by Fiona M. Scott Morton

  • 1997 Royalty rates, sub licensing considerations and joint ventures
    by Elli Malki

  • 1997 The economic sense of royalty rates
    by Elli Malki

  • 1997 Intellectual property and the valuation of biotechnology
    by Elli Malki

  • 1997 Entry Decisions in the Generic Pharmaceutical Industry
    by Fiona M. Scott Morton

  • 1997 The Objectives of the FDA's Office of Generic Drugs
    by Fiona Scott Morton

  • 1997 Economic consequences of the German environmental liability act: Capital market response for the chemical industry
    by Bartsch, Elga

  • 1996 Characteristics of Demand for Pharmaceutical Products : an Examination of four Cephalosporins
    by Ellison, S & Cockburn, I & Griliches, A & Hausman, J

  • 1996 Rewarding Failure: Performance Related Pay in a Pharmaceutical research and Development Company
    by Randle, K.

  • 1995 R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
    by Joseph A. Dimasi & Grabowski, Henry G. & Vernon, John

  • 1995 Genotyping by Combinatorial Optimization Techniques
    by Lancia, G.

  • 1995 Do Other Firms Matter in Oligopolies?
    by Haskel, Jonathan & Scaramozzino, Pasquale

  • 1995 The transmission of information in the transacting of primary products: the case of quality improvement in Thailand's natural rubber production
    by Shigetomi, Shinichi

  • 1994 Fast Growing Small Entrepreneurial Firms and their Venture Capital Backers: an Applied Principal-Agent Analysis
    by Gavin C Reid

  • 1994 The Roles of Marketing, Product Quality and Price Competition in the Growth and Composition of the U.S. Anti-Ulcer Drug Industry
    by Ernst R. Berndt & Linda Bui & David Reiley & Glen Urban

  • 1993 Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry
    by Rebecca Henderson & Iain Cockburn

  • 1993 Generics and New Goods in Pharmaceutical Price Indexes
    by Zvi Griliches & Iain Cockburn

  • 1993 Pricing, Profits, and Technological Progress in the Pharmaceutical Industry
    by F. M. Scherer

  • 1990 Aplicaciones de la biotecnología en la industria agroalimentaria
    by Juan Blas Domínguez

  • Overseas Acquisition Versus Greenfield Foreign Investment: Which Internationalization Strategy is better for Indian Pharmaceutical Enterprises?
    by Jaya Prakash Pradhan & Abhinav Alakshendra

  • Global competitiveness of Indian Pharmaceutical Industry: Trends and Strategies
    by Jaya Prakash Pradhan

  • Direct-to-Consumer Advertising in Pharmaceutical Markets
    by Kurt R Brekke & Michael Kuhn

  • This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.